PMID- 11746533
OWN - NLM
STAT- MEDLINE
DCOM- 20020304
LR  - 20191210
IS  - 0733-2459 (Print)
IS  - 0733-2459 (Linking)
VI  - 16
IP  - 2
DP  - 2001
TI  - Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem 
      cell apheresis.
PG  - 82-7
AB  - Donor lymphocyte transfusion has gained considerable interest as adoptive 
      cellular immunotherapy for prevention or treatment of relapse after allogeneic 
      stem cell transplantation. This study was designed to compare the yield of 
      CD3(+), CD3(+)4(+), CD3(+)8(+), CD19(+), CD3(-)56(+)16(+), and CD34(+) cells 
      contained in apheresis products from 61 consecutive non-cytokine treated, human 
      leukocyte antigen (HLA)-matched donors for lymphocyte collection with the 
      corresponding apheresis-derived cell yield from 112 consecutive, HLA-matched 
      donors for blood stem cell collection who received recombinant human granulocyte 
      colony stimulating factor (rhG-CSF, filgrastim) 6 microg/kg every 12 hours until 
      cell collection was completed. Apheresis was started on day 4 or 5 of rhG-CSF 
      treatment. The yield of lymphoid subsets was significantly different in the two 
      sample groups, rhG-CSF treated product yields exceeding untreated product yields 
      by a median of 2.1-fold (range: 1.3-2.6). However, the CD34(+) cell yield in 
      rhG-CSF-treated apheresis products exceeded untreated products by 26-fold. A 
      single untreated apheresis procedure was usually sufficient to collect a target 
      dose of 1 x 10(8)/kg CD3(+) cells. Untreated apheresis products contained a 
      median of 0.2 x 10(6)/kg CD34(+) cells. A potential engraftment dose of > or =0.5 
      x 10(6) CD34(+) cells per kg of recipient body weight was contained in 16% of 57 
      untreated apheresis products. One single apheresis performed in a normal, 
      untreated donor provides a sufficient amount of CD3(+) cells for adoptive 
      immunotherapy. Compared with that of an rhG-CSF stimulated apheresis product, the 
      CD34(+) cell count is usually, but not always, below the engraftment dose range. 
      RhG-CSF treatment has little effect on the yield of lymphoid subsets collected by 
      apheresis but is highly selective of the release of CD34(+) cells. This report 
      provides baseline data for studies that will show whether other cytokines such as 
      granulocyte macrophage colony stimulating factor (GM-CSF) and/or Flt-3 Ligand can 
      immunomodulate allotransfusates in vivo to improve the graft-vs.-leukemia (GVL) 
      effect after allogeneic stem cell transplantation, while lowering the incidence 
      and severity of graft-vs.-host disease (GVHD).
CI  - Copyright 2001 Wiley-Liss, Inc.
FAU - Korbling, M
AU  - Korbling M
AD  - The University of Texas M.D. Anderson Cancer Center, Division of Medicine, 
      Department of Blood and Marrow Transplantation, Houston, Texas 77030, USA. 
      mkorblin@mdanderson.org
FAU - Giralt, S
AU  - Giralt S
FAU - Khouri, I
AU  - Khouri I
FAU - Mirza, N
AU  - Mirza N
FAU - Donato, M
AU  - Donato M
FAU - Anderlini, P
AU  - Anderlini P
FAU - Fischer, H
AU  - Fischer H
FAU - Andreeff, M
AU  - Andreeff M
FAU - McMannis, J
AU  - McMannis J
FAU - Champlin, R
AU  - Champlin R
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - J Clin Apher
JT  - Journal of clinical apheresis
JID - 8216305
RN  - 0 (Antigens, CD)
RN  - 0 (Recombinant Proteins)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - PVI5M0M1GW (Filgrastim)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, CD/analysis
MH  - Blood Cell Count
MH  - Blood Donors
MH  - Body Weight
MH  - Female
MH  - Filgrastim
MH  - Graft vs Host Disease/etiology/prevention & control
MH  - Graft vs Leukemia Effect
MH  - Granulocyte Colony-Stimulating Factor/pharmacology
MH  - Hematopoietic Stem Cell Mobilization
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Histocompatibility
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects/*methods
MH  - Leukapheresis/*methods
MH  - Leukemia/blood/therapy
MH  - Lymphocyte Count
MH  - Lymphocyte Subsets
MH  - *Lymphocyte Transfusion/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Recombinant Proteins
MH  - Transplantation, Homologous
EDAT- 2001/12/18 10:00
MHDA- 2002/03/05 10:01
CRDT- 2001/12/18 10:00
PHST- 2001/12/18 10:00 [pubmed]
PHST- 2002/03/05 10:01 [medline]
PHST- 2001/12/18 10:00 [entrez]
AID - 10.1002/jca.1017 [pii]
AID - 10.1002/jca.1017 [doi]
PST - ppublish
SO  - J Clin Apher. 2001;16(2):82-7. doi: 10.1002/jca.1017.